Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1

Liang, Zhongxing; Wu, Hui; Xia, Jing; Li, Yuhua; Zhang, Yawei; Huang, Ke; Wagar, Nicholas; Yoon, Younghyoun; Cho, Heidi T.; Scala, Stefania; Shim, Hyunsuk

doi:10.1016/j.bcp.2009.10.017

Cited by 300 publications

(227 citation statements)

References 35 publications

Supporting

Mentioning

216

Contrasting

Unclassified

Order By: Relevance

“…Indeed, one of the major co-activators for ERα, AIB1, is a target for miR-17 and miR-106, which are found to be dysregulated in breast cancer cells exhibiting drug resistance (154,155). The transcriptional co-repressor, receptor interacting protein 140 (RIP140), was found to be targeted by miR-346, which is downregulated in endocrine-resistant cell lines (156), indicating a role for miRNAs in regulating estrogen-responsive genes.…”

Section: Role For Autophagy In Anti-estrogen Resistancementioning

confidence: 99%

Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review)

et al. 2014

View full text Add to dashboard Cite

Abstract. Anti-estrogens such as tamoxifen are widely used in the clinic to treat estrogen receptor-positive breast tumors. Patients with estrogen receptor-positive breast cancer initially respond to treatment with anti-hormonal agents such as tamoxifen, but remissions are often followed by the acquisition of resistance and, ultimately, disease relapse. The development of a rationale for the effective treatment of tamoxifen-resistant breast cancer requires an understanding of the complex signal transduction mechanisms. In the present study, we explored some mechanisms associated with resistance to tamoxifen, such as pharmacologic mechanisms, loss or modification in estrogen receptor expression, alterations in co-regulatory proteins and the regulation of the different signaling pathways that participate in different cellular processes such as survival, proliferation, stress, cell cycle, inhibition of apoptosis regulated by the Bcl-2 family, autophagy, altered expression of microRNA, and signaling pathways that regulate the epithelial-mesenchymal transition in the tumor microenvironment. Delineation of the molecular mechanisms underlying the development of resistance may aid in the development of treatment strategies to enhance response and compromise resistance.

show abstract

Section: Role For Autophagy In Anti-estrogen Resistancementioning

confidence: 99%

Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review)

et al. 2014

View full text Add to dashboard Cite

show abstract

“…It will be interesting to verify if the same phenomenon is also observed in patient tumor samples. The regulation of the other two major multidrug resistance transporters, Pglycoprotein/MDR1 and MRP1, by miR-451, -27a and -326, respectively, have also been reported (Kovalchuk et al, 2008;Liang et al, 2010). More importantly, modulation of miRNA expression or function can alter sensitivity of cancer cells to anticancer drugs (Zhu et al, 2008;Pan et al, 2009;Blower et al, 2008).…”

Section: Microrna-mediated Regulation Of Abcg2mentioning

confidence: 95%

Multidrug Resistance Transporters – Roles in maintaining Cancer Stem-Like Cells

Tõ¹,

Kenneth²,

Fu³

2011

Stem Cells in Clinic and Research

View full text Add to dashboard Cite

“…miR-326 is a suppressor of the Hedgehog, Notch and mitogen-activated protein kinase signaling pathways that are associated with brain tumors (61)(62)(63), and may block expression of multidrug resistance-associated proteins in breast cancer (64). Low expression levels of miR-326 are correlated with poor OS in patients with pathological grade III-IV glioma (65).…”

Section: A B C Dmentioning

confidence: 99%

Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum

Zhu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Pemetrexed combined with platinum is a first-line therapy used to treat patients with advanced non-small cell lung cancer (NSCLC) that exhibit negative or unknown epidermal growth factor receptor (EGFR) mutational status or anaplastic lymphoma kinase (ALK) rearrangements. Lung adenocarcinoma (LAC) is the primary type of NSCLC. In order to prevent overtreatment, it is necessary to identify patients with LAC who may not benefit from certain chemotherapies. Patients recruited in the present study (n=129) were diagnosed with advanced LAC and received first-line pemetrexed and platinum-based chemotherapy. A microRNA (miR) microarray was used to screen the plasma miR expression profiles in a screening set of eight patients prior to and following treatment. Specifically, plasma miR-25, miR-21, miR-27b, miR-326, miR-483-5p and miR-920 were selected for reverse transcription-quantitative polymerase chain reaction analysis in a training set (n=44) prior to treatment. The screening and training set patients were all non-smokers with no prior history of serious or chronic disease. The ∆∆Cq values of these miRs were compared between the group that showed benefit from pemetrexed and platinum treatment and the group that did not. Consequently, the ∆∆Cq values of miR-25, miR-21, miR-27b and miR-326 were further determined in a validation set (n=77). The results of the present study demonstrate that plasma expression levels of miR-25, miR-21, miR-27b and miR-326, in the training and validation sets prior to treatment, were significantly different between the benefit and non-benefit groups (P≤0.001). The expression of miR-25, miR-21, miR-27b and miR-326 was upregulated in the non-benefit group and this elevation was positively correlated with decreased progression-free survival (PFS; P≤0.001). In addition, the predictive power of each miR was evaluated through receiver operating characteristic curves, in which miR-25 exhibited the highest degree of accuracy (area under the curve, 0.926; 95% confidence interval, 0.881-0.971). These results indicate that overexpression of plasma miR-25, miR-21, miR-27b and miR-326, prior to treatment, in patients with advanced LAC is predictive of non-benefit from first-line pemetrexed and platinum-based chemotherapy, and is associated with decreased PFS. Among these four miRs, miR-25 exhibited the highest degree of accuracy in predicting insensitivity, suggesting it is the most promising biomarker.

show abstract

Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1

Cited by 300 publications

References 35 publications

Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review)

Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review)

Multidrug Resistance Transporters – Roles in maintaining Cancer Stem-Like Cells

Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum

Contact Info

Product

Resources

About